Preclinical studies show that genetic or pharmacological inhibition of RANKL can decrease the formation of preneoplastic lesions, slow tumor progression, and reduce mammary tumorigenesis in Brca1-deficient mouse models [268]. The gene discussed is BRCA1; the disease is neoplasm.